Andres ForeroSpringer New YorkVaklavas C, LoBuglio A, Saleh M, Yelin M, Forero A. CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE). In: Phillips GL, ed. Antibody-Drug Conjugates and Immunotoxins: Springer New York). 2013; 211-220....
转移性乳腺癌与第二代抗体药物管理共轭: 侧重于 Glembatumumab Vedotin (CDX-011,CR011-vcMMAE)。 翻译结果4复制译文编辑译文朗读译文返回顶部 变形的乳腺癌的管理有第二代抗体药物共轭的:在Glembatumumab Vedotin (CDX-011, CR011-vcMMAE)的焦点。
GPNMB is a melanoma-associated glycoprotein that is targeted by the CR011-vcMMAE antibody-drug conjugate (ADC). Previous studies have shown that CR011-vcMMAE induces the apoptosis of GPNMB-expressing tumor cells in vitro and tumor regression in xenograft models. This ADC is currently in clinical ...
CR011-vcMMAEAntibody–drug conjugate (ADC)XenograftTo investigate the pharmacological properties of the CR011-vcMMAE fully human antibody–drug conjugate (ADC), such as dose titrations, quantitation of the time (days) to complete regression, pharmacokinetics, and schedule dependency. Our prior ...
The terminology has thus become confused, with many ambiguities and synonyms (Bagby 1985).doi:10.2165/00128413-200816560-00020Inpharma WeeklySpringer International PublishingInpharma Weekly
Enrolment is complete for a phase II trial of the monoclonal antibody CR011-vcMMAE in metastatic melanoma
The development of monoclonal antibodies as cancer therapeutic agents has improved the outlook for many patients as evidenced by the number of such drugs that have been approved for oncologic indications [1]. Monoclonal antibodies allow selective killing of malignant cells (targeted therapy) with ...